Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

atenolol

APX-ATENOLOL

atenolol (APX-ATENOLOL) is a beta-1 adrenergic receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 20
Pipeline programs 2
News articles 0
Drug details — atenolol
US status
approved
Class
—
Route
INJECTION
Patents
20
Programs
2
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

atenolol (APX-ATENOLOL) is a beta-1 adrenergic receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN atenolol
Brand APX-ATENOLOL
Mechanism Beta-1 adrenergic receptor antagonist
Target Beta-1 adrenergic receptor
Route INJECTION
Formulation INJECTABLE
Originator Alphapharm Pty Ltd

Mechanism of action

Beta-1 adrenergic receptor antagonist

Primary target: Beta-1 adrenergic receptor

Approval history

Authority Status Date
FDA approved —
TGA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Atenolol Approved · Cardiff Oncology · Marfan Syndrome
  2. BA-SCAD Approved · Cardiol Therapeutics · Spontaneous Coronary Artery Dissection.

Related & competitor drugs

Browse all drugs
  1. acebutolol hydrochloride Beta-1 adrenergic receptor antagonist
  2. bisoprolol fumarate Beta-1 adrenergic receptor antagonist
  3. dobutamine hydrochloride Beta-1 adrenergic receptor agonist
  4. dopamine hydrochloride Cardiovascular system (C01)
  5. esmolol hydrochloride Beta-2 adrenergic receptor antagonist
  6. metoprolol succinate Beta-1 adrenergic receptor antagonist

Related patents

Browse patents Alphapharm Pty Ltd patent hub

  1. US 12419888

    Methods of treating elevated plasma cholesterol

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12383540

    Compounds that modulates AMPA receptor function

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11639490

    Device and method for producing and purifying exosomes

    Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11298345

    Compounds that modulates AMPA receptor function

    Expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11186567

    AMPA receptor potentiators

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11083696

    Dispersion anaesthetic device

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10788490

    Dried cellulose-treated tissue for in-vitro complement activation assays and diagnostic kits

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10564161

    Method for identifying a bacterial infection

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10209255

    Method for identifying a bacterial infection

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10005810

    Process for preparing nucleoside prodrugs

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9918986

    Methods and compounds for preventing osteoarthritis

    Expires Mon Mar 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9896729

    Method for diagnosing a neurodegenerative disease

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9867795

    Nitrated lipids and methods of making and using thereof

    Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9861606

    Therapeutic for treating inflammatory lung disorders

    Expires Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9827394

    Dispersion anaesthetic device

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9789134

    Agent for the selective adjustment of blood lipids

    Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9522156

    Nitrated lipids and methods of making and using thereof

    Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9295678

    Nitrated lipids and methods of making and using thereof

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9006473

    Nitrated lipids and methods of making and using thereof

    Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8835380

    Therapeutic conjugates

    Expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is atenolol?

atenolol (APX-ATENOLOL) is a beta-1 adrenergic receptor antagonist. Associated with Alphapharm Pty Ltd. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for atenolol?

APX-ATENOLOL is a marketed brand name for atenolol. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of atenolol?

atenolol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.